You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Sonic Healthcare Limited (SHL) is an international medical diagnostics company, offering laboratory medicine/pathology and radiology services to the medical community. The company is structured as a decentralised federation of medically-led diagnostic practices, with the head office in Sydney, Australia. SHL provides the services and infrastructure in eight countries: Australia; New Zealand; the UK; Germany; Switzerland; Belgium; Ireland; and the USA.
Strategy Analysis: The domestic strategy is to retain cost leadership through the reinvestment of capital into new technology. The building of new facilities delivers cost savings through leveraging new technology. The international strategy is to add bolt on acquisitions to the growing hub and spoke network within Europe and the US. These international facilities have surplus capacity so any acquisitions will enable rationalisation of processing and leverage administration cost over a larger operation. SHL is also focused on more specialist diagnostic services and is developing centres of excellence for diagnosing complex medical conditions. SHL¬īs use of different brands means it can address niche specialist services as well as mass processing to leverage its skill set and reduce costs.
Sonic Healthcare reported NPAT up 5.4% to $150.63m for the half-year ended 31 December 2012. Revenues from ordinary activities were $1.7bn, up 3.4% from the same period last year. Diluted EPS was 38.0 cents compared to 36.5 cents last year. Net operating cash flow was $222.38m compared to $224.3m last year. The interim dividend declared was 25 cents compared with 24 cents last year. The company gave full year guidance in August 2012 of EBITDA growth of 5-10% over the 2012 level of $624.0m, on a constant currency basis (applying 2012 average currency exchange rates to 2013). After seven months of trading and allowing for larger than expected fee changes in Germany in the second half, unexpected anatomical pathology fee cuts in the USA, lower than expected growth in the USA, and Superstorm Sandy impacts, the company is expecting a full-year result at the lower end of the guidance range.
The Age 20/06/2013 |
Pre-split trading of shares in "New Newscorp," the print media-heavy spin-out from News Corp began quietly on Wednesday, and it will take a while to work out where the new vehicle is headed.
The Age 20/06/2013 |
Local councils that lost millions on investments made through Lehman Brothers have suffered a major setback, after the US arm of the failed bank blocked a deal that would have delivered the investors up to $210 million.
IMPORTANT: This information has been prepared without taking into account your objectives, financial situation or needs and you should consider if the information is appropriate for you before making an investment decision. Neither InvestSMART Financial Services Pty Ltd nor any of its Related Companies make any recommendations as to the merits of any investment opportunity referred to in its emails or its related websites. Product disclosure statements for financial products offered through InvestSMART can be downloaded from this website or obtained by contacting 1300 880 160. You should consider the product disclosure statement before making a decision about the product. All indications of performance returns are historical and can not be relied upon as an indicator for future performance.